Recent studies suggest that combining CK-18 with other markers, like FGF-21, could enhance diagnostic accuracy, particularly in identifying MASLD phenotypes and assessing the risk of progression to NASH.5,18,19 Although CK-18 levels were higher in MASLD groups, the lack of statistical significance may reflect the early-stage nature of the disease in this cohort or variability in the biomarker’s sensitivity for detecting minimal fibrosis. The gene discussed is KRT18; the disease is metabolic dysfunction-associated steatohepatitis.